Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
08/05/2012
11/04/2012
19/03/2012
20/02/2012
06/02/2012
26/01/2012
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
News: 1-6 / 6
Archive
2012
2011
2010
